Amyl Therapeutics
Amyl Therapeutics is a preclinical-stage biotechnology company developing Pan-Amyloid Immunotherapy, a universal approach to treating amyloid-mediated neurodegenerative diseases. Their mission is to develop a treatment that targets all toxic amyloid species across neurodegenerative and systemic amyloid-mediated diseases, with the potential to be both preventative and curative. The company is supported by an experienced team and strategic collaborations, aiming to transform the standard of care for amyloid-related diseases.
Industries
Nr. of Employees
small (1-50)
Amyl Therapeutics
LegiaPark, Boulevard Patience et Beaujonc 3, box 12, 4000 Liège, Belgium
Patents
Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
US-11723951-B2
View DetailsPolypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
US-9988444-B2
View DetailsBacteriophage gene 3 protein compositions and use as amyloid binding agents
US-9688728-B2
View DetailsBacteriophage gene 3 protein compositions and use as amyloid binding agents
US-9493515-B2
View Details
Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
US-11723951-B2
View DetailsPolypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
US-9988444-B2
View DetailsBacteriophage gene 3 protein compositions and use as amyloid binding agents
US-9688728-B2
View DetailsBacteriophage gene 3 protein compositions and use as amyloid binding agents
US-9493515-B2
View DetailsProducts
Pan-amyloid immunotherapy candidates (preclinical)
Preclinical therapeutic candidates designed to selectively bind the structural signature common to amyloid fibrils (cross-β sheet), intended to neutralize multiple toxic aggregates and clear mature fibrils while minimizing inflammatory risk and improving CNS exposure.
Pan-amyloid immunotherapy candidates (preclinical)
Preclinical therapeutic candidates designed to selectively bind the structural signature common to amyloid fibrils (cross-β sheet), intended to neutralize multiple toxic aggregates and clear mature fibrils while minimizing inflammatory risk and improving CNS exposure.
Services
End-to-end preclinical R&D activities to discover, optimize and characterize immunotherapeutic candidates targeting amyloid aggregates.
End-to-end preclinical R&D activities to discover, optimize and characterize immunotherapeutic candidates targeting amyloid aggregates.
Expertise Areas
- Preclinical immunotherapy development
- Neurodegenerative disease therapeutics (amyloid-mediated)
- Cross-amyloid targeting strategies
- Antibody and biologic engineering for CNS delivery
Key Technologies
- Antibody-based immunotherapy
- Targeting cross-β sheet amyloid conformation
- AI-driven molecule optimization
- Bioassay development and analytics
News & Updates
Pierre Vandepapelière, CEO, attended the LSX Nordic Congress in Bergen, presenting their breakthrough therapy for neurodegenerative diseases.
Pierre Vandepapelière presented Amyl's technology at the Swiss Biotech Day in Basel.
Pierre Vandepapelière attended the LSX World Congress in London, showcasing their Pan-Amyloid Immunotherapy.
Details about upcoming conferences including the New Horizons in Neurodegeneration in Leuven, PEGS Europe in Lisbon, and the Boston BIO International Convention.
Damien Toulorge represented Amyl at the BIO International Convention in Boston, highlighting their advances.
Pierre Vandepapelière, CEO, attended the LSX Nordic Congress in Bergen, presenting their breakthrough therapy for neurodegenerative diseases.
Pierre Vandepapelière presented Amyl's technology at the Swiss Biotech Day in Basel.
Pierre Vandepapelière attended the LSX World Congress in London, showcasing their Pan-Amyloid Immunotherapy.
Details about upcoming conferences including the New Horizons in Neurodegeneration in Leuven, PEGS Europe in Lisbon, and the Boston BIO International Convention.
Damien Toulorge represented Amyl at the BIO International Convention in Boston, highlighting their advances.